Addiction - Articles | CARLAT PUBLISHING

Expert Q&A

Digital Addictions

June 1, 2026

James Sherer, MD. Psychiatrist in private practice offering psychotherapy, medication management, and lifestyle modification.

Dr. Sherer has no financial relationships with companies related to this material.

Apps are engineered to hook users. Here’s how to recognize and treat digital addiction in your patients.

When Doctors Get Addicted: Why the System Fails Them

October 19, 2025

Daniel Carlat, MD

Dr. Peter Grinspoon’s story is a call to fix how we treat physician addiction.

Psychedelics and Addiction Psychiatry

October 13, 2025

Noah Capurso, MD and Snehal Bhatt, MD

Today, we'll be talking about psychedelics and addiction psychiatry, what they are, how they work, and what the research actually tells us.

The Rise of Long-Acting Buprenorphine

September 29, 2025

Noah Capurso, MD and Geneva Valeska

There are two variations of long-acting injectable buprenorphine on the market. But what differentiates them, who might benefit, and how well do they work? Find out in today’s podcast.

How to Talk to Patients About Porn Use

August 29, 2025

Daniel Carlat, MD

We ask about alcohol.

We ask about weed.

Sometimes we even ask about TikTok.

But porn?

Research Update

Topiramate Versus Naltrexone for Alcohol Use Disorder

August 14, 2025

Matt Settle NP

Matt Settle, NP. Mr. Settle has no financial relationships with companies related to this material.

Topiramate matches naltrexone for AUD—and adds perks for patients with obesity, migraines, or binge eating.

4 Rationalizations for Cannabis Use—And How to Respond

May 26, 2025

Daniel Carlat, MD

Research Update

Long-Term Patient Outcomes with Buprenorphine for Opioid Use Disorder

January 1, 2025

Peter J. Farago, MD.

Peter Farago, MD. Dr. Farago has no financial relationships with companies related to this material.

Researchers compare outcomes in patients who take buprenorphine for shorter and for longer. Their findings are revealing.

Expert Q&A

Managing Withdrawal From Multiple Substances

January 1, 2025

Darius Rastegar, MD

Darius Rastegar, MD

Associate professor of medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

Dr. Rastegar has no financial relationships with companies related to this material.

Substance use disorders are highly comorbid with one another and it is therefore common to have patients presenting for care withdrawing from multiple substances at one time. Here, Dr. Rastegar discusses how to assess patients with multiple withdrawal syndromes and how to treat them.

Clinical Update

Effective Management of Buprenorphine-Precipitated Opioid Withdrawal

January 1, 2025

Jaewon Lee, MD, MPH

Jaewon Lee, MD, MPH. PGY-2, psychiatry resident, University of Rochester Medical Center, Rochester, NY.

Dr. Lee has no financial relationships with companies related to this material.

Buprenorphine is a first-line treatment for opioid use disorder, however, given buprenorphine to a patient who still has opioids in their system can precipitate severe withdrawal. Careful assessment of withdrawal can minimize the risk, but despite our best efforts, precipitated withdrawal can still occur. In this article, we review what to do for our patients experiencing buprenorphine-precipitated opioid withdrawal.